Product Name: Dexmedesed<sup>TM</sup> (dexmedetomidine hydrochloride) Sterile

**Injectable Solution** Issue Date: 07/12/2017

Version No: 1 Page 1 of 15



SECTION 1: IDENTIFICATION			
1.1 Product identifier			
Product name:	Dexmedesed™ (dexmedetomidine hydrochloride) Sterile Injectable Solution		
Synonyms:	Not Available		
Proper Shipping name:	Not Available		
Other means of identification:	None		
1.2 Relevant identified uses	of the substances or mixture and uses advised against		
Recommended uses:	Bulk formulated pharmaceutical mixture/formulated pharmaceutical product packaged in final form for veterinary use; indicated as a sedative and analgesic for cats and dogs.		
Uses advised against:	Not for human use.		
1.3 Name, Address, and Tele	1.3 Name, Address, and Telephone of the Responsible Party		
Address:	Dechra Veterinary Products 7015 College Boulevard Suite 525 Overland Park KS 66211		
Telephone:	1-866-933-2472 (Monday-Friday: 8:00 AM-5:00 PM EST)		
Distributor name (Canada):	Dechra Veterinary Products		
Address:			
Telephone:	(855) 332-9334		
Website:	www.dechra.ca		
Email:	Not Available		
1.4 Emergency Telephone Nu	umbers		
Emergency phone (CA)	(855) 332-9334		
	1-866-933-2472 (Monday-Friday: 8:00 AM-5:00 PM EST)		

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 2 of 15



# **SECTION 2: HAZARDS IDENTIFICATION**

# 2.1 Classification of the substance or mixture

This mixture is not classified as dangerous/hazardous according to directive 1999/45/EC, Regulation EC No 1272/2008 (EU CLP), and applicable US regulations.

Drugs in the finished state and intended for the final user are not subject to labeling in the US, EU or Canada. Please consult the prescribing/packaging information. The classification and labelling listed below is for bulk Dexmedesed<sup>TM</sup> Sterile Injectable Solution.

US, EU or Canada. Please consult the prescribing/packaging information. The classification and labelling listed below is for bulk Dexmedesed <sup>TM</sup> Sterile Injectable Solution.			
Classification according to regulation (EC) No 1272/2008 [GHS]:	Not classified		
Classification according to Directive 67/548/EEC or 1999/45/EC:			
2.2 Label Elements			
CLP/GHS hazard pictogram:	None required		
CLP/GHS signal word:	None required		
US signal word:	Attention		
US Hazard overview:	None required		
CLP/GHS hazard statement(	s):		
None required			
CLP/GHS Precautionary Statement(s) Prevention:			
None required			
CLP/GHS Precautionary State	CLP/GHS Precautionary Statement(s) Response:		
None required	None required		
CLP/GHS Precautionary Sta	tement(s) Storage:		
None required			
CLP/GHS Precautionary Sta	tement(s) Disposal:		
None required			
EU symbol/indication of dan	ger:		
None required			
Risk (R) Phrase(s):			
None required			
Safety advice:			
None required			

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 3 of 15



## 2.3 Other Hazard Information

Dexmedetomidine hydrochloride is an α2-adrenergic agonist with potent sedative properties. The most common adverse effects reported with clinical use of mixtures containing dexmedetomidine are hypotension, bradycardia, and dry mouth. Other adverse effects include transient hypertension, fever, hypoxia, and anemia, and tachycardia episodes.

Symptoms of withdrawal (e.g., nausea, vomiting, and agitation) have been reported following discontinuation after 7 days of repeated administration.

Note: See Section 16 for full text of EU and GHS classifications. The EU symbol/ indicator of danger, R Phrases and Safety Advice are based on Directive 67/548/EEC or 1999/45/EC. The GHS classifications are based on Regulation (EC) 1272/2008. See Section 16 for full text of EU and GHS classifications.

# **SECTION 3: INFORMATION ON THE INGREDIENTS**

## 3.1 Substances

See section below for composition of mixtures

## 3.2 Mixtures

1. CAS # 2. EINECS/ELINCS No.	% weight	Name	EU Classification	GHS Classification
1. 145108-58-3 2. N/a	<0.1%	Dexmedetomidine hydrochloride	Harmful – Xn: R63	STOT-S3: H336; RT2: H361d
1. 7647-14-5 2. 231-598-3	<1%	Sodium chloride	Not classified	Not classified

**Note:** The ingredient(s) listed above are considered dangerous/hazardous. Sodium chloride is included because it has an OEL. See Section 16 for full text of EU and GHS classifications. The EU classification is based on Directive 67/548/EEC and the GHS classification is based on Regulation (EC) 1272/2008.

# **SECTION 4: FIRST AID MEASURES**

# 4.1 Description of first aid measures

4.1 Description of first aid measures		
Eye contact:	If easy to do, remove contact lenses, if worn. Immediately flush eyes with copious quantities of water for at least 15 minutes. If irritation occurs or persists, notify medical personnel and supervisor and show the package leaflet or the label to the medical practitioner.	
Skin contact:	Wash exposed area with soap and water and remove contaminated clothing/shoes. If irritation occurs or persists, notify medical personnel and supervisor and show the package leaflet or the label to the medical practitioner	

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 4 of 15



Inhalation:	Inhalation is highly unlikely due to the nature of the product and how it is packaged and administered.  Immediately move exposed subject to fresh air. If not breathing, give artificial respiration. If breathing is labored, administer oxygen. Immediately notify medical personnel and supervisor and show the
Ingestion:	Do not induce vomiting unless directed by medical personnel. Do not give anything to drink unless directed by medical personnel. Never give anything by mouth to an unconscious person. Notify medical personnel and supervisor and show the package leaflet or the label to the medical practitioner.
Self-injection:	•

# 4.2 Most important symptoms and effects, both acute and delayed

See Sections 2 and 11

# 4.3 Indication of immediate medical attention and special treatment needed

Contains dexmedetomidine, a potent sedative.

Medical conditions aggravated by exposure: None known or reported.

Treat symptomatically and supportively.

Refer to current prescribing information or to local poison control information centers.

# **SECTION 5: FIRE FIGHTING MEASURES**

5.1 Extinguishing media		
Suitable:	Select extinguishing media suitable for surrounding area.	
Unsuitable:	There is no restriction on the type of extinguisher which may be used.	
5.2 Special hazards arising from the substance or mixture		
Fire incompatibility:	None known	
5.3 Special protective actions for fire-fighters:		
Firefighting:	Alert Fire Brigade and tell them location and nature of hazard. Wear full protective clothing and a self-contained breathing apparatus with a full face-piece operated in the pressure demand or other positive pressure mode. Decontaminate all equipment after use. Prevent, by any means available, spillage from entering drains or water courses.	
Fire / explosion hazard:	No explosivity or flammability data identified. As product is in an aqueous solution, it is not expected to be flammable or explosive.  May emit carbon monoxide, carbon dioxide, oxides of nitrogen or chloride and sodium-containing compounds.	

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 5 of 15



# SECTION 6: ACCIDENTAL RELEASE MEASURES

# 6.1 Personal precautions, protective equipment and emergency procedures

If product is released or spilled, take proper precautions to minimize exposure by using appropriate personal protective equipment (see Section 8).

Area should be adequately ventilated. Do not breathe dust/mist/vapors/spray.

# **6.2 Environmental Precautions**

Do not empty into drains. Avoid release to the environment.

## 6.3 Methods and material for containment and cleaning up

Spills are unlikely due to the nature of the product and how it is packaged

Minor Spills:	Clean up all spills immediately. Avoid breathing vapours and contact with skin and eyes. Soak up material with absorbent, e.g., paper towels. Control personal contact with the substance, by using protective equipment.
Major Spills:	Cordon off spill area and minimize the spreading of spilled material

Collect spilled material, absorbent, and rinse water into suitable containers for proper disposal in accordance with applicable waste disposal regulations (see Section 13).

Decontaminate the area twice.

Prevent, by any means available, spillage from entering drains or water

course.

## **SECTION 7: HANDLING AND STORAGE**

# 7.1 Precautions for safe handling

Safe Handling:	Wear suitable protective clothing when handling the product. When handling, <b>DO NOT</b> eat, drink or smoke. Always wash hands with water after handling. In case of accidental self-injection seek medical advice immediately and show the package leaflet or the label to the physician. Observe manufacturer's storage and handling recommendations.		
Other Information:	Keep out of the reach and sight of children.		
7.2 Conditions for safe storage, including any incompatibilities			
Suitable Container:	Check that containers are clearly labelled. Store at controlled room temperatures 68-77°F (20-25°C). Protect from freezing.		
Storage incompatibility:	None known.		

# 7.3 Specific end uses

Not available

Product Name: Dexmedesed™ (dexmedetomidine hydrochloride) Sterile

**Injectable Solution** Issue Date: 07/12/2017

Version No: 1 Page 6 of 15



SECTION 8: EXPOSURE CONTROLS / PERSONAL PROTECTION
8.1 Control parameters
DERIVED NO EFFECT LEVEL - DNEL (EU)
Not Available
PREDICTED NO EFFECT LEVEL - PNEC (EU)
Not Available
OCCUPATIONAL EXPOSURE LIMITS (OFL)

	, ,	
INGREDIENT DATA:		
Not Available		
EMERGENCY LIMITS:		
Not Available		
Ingredient	Original IDLH	Revised IDLH
Not Available		
8.2 Exposure controls		
Appropriate engineering controls		
Personal protection:		
Eye and face protection:	, , ,	necessary. Base the choice of and potential for contact with
Skin protection:		likely. Base the choice of skin potential for skin contact and

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 7 of 15



None required for the normal handling of packaged product. Wear nitrile or other impervious gloves if skin contact is possible. Double gloves should be considered. When the material is dissolved or suspended in an organic solvent, wear gloves that provide protection against the solvent.
Wear appropriate clothing.
No special equipment needed when handling small quantities. Wash hands in the event of contact with this mixture, especially before eating, drinking or smoking. Protective equipment is not to be worn outside the work area (e.g., in common areas or out-of-doors).
Not applicable
Not applicable

# 8.3 Environmental exposure controls

Avoid release to the environment and operate within closed systems wherever practicable. Air and liquid emissions should be directed to appropriate pollution control devices. In case of spill, do not release to drains. Implement appropriate and effective emergency response procedures to prevent release or spread of contamination and to prevent inadvertent contact by personnel.

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 8 of 15



## **SECTION 9: PHYSICAL AND CHEMICAL PROPERTIES**

## 9.1 Information on basic physical and chemical properties

Appearance: Dexmedesed<sup>TM</sup>: Clear, colorless liquid

Container:

Physical state: Liquid

Odor: Odorless

Odor Threshold: Not available pH (as supplied): Not available

Melting point / freezing point (degrees C): Not available Initial boiling point and boiling range: Not available

Flash Point: In water – no flash point Evaporation rate: Not available Flammability: Not available

Upper/lower flammability or explosive limits: Not available

Vapor pressure: Not available

Relative Density (at degrees C): Not available

Solubility in water and solvents (mg/l): Freely soluble in water

Vapour density: Not available

Auto ignition temperature (degrees C): Not available Decomposition temperature (degrees C): Not available

Viscosity: (degrees C): Not available Explosive properties: Not available Oxidising properties: Not available Partition Coefficient: Not available Molecular weight: Not available

Taste: Not available

**Surface tension:** Not available **Volative component:** Not available

Gas group: Not available pH as a solution: Not available

VOC g/L: Not available

# 9.2 Other information

Not Available

10: REACTIVITY AND STABILITITY		
10.1 Reactivity:	See Section 7.	
10.2 Chemical stability:	Product is considered stable.	
10.3 Possibility of hazardous reactions:	The product is not considered to be hazardous if used as per instructions.	
10.4 Conditions to avoid:	Avoid extreme temperatures. Do not freeze.	
10.5 Incompatible materials:	See section 7.	

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 9 of 15



10.6 Hazardous decomposition:	See Section 5.	See Section 5.					
SECTION 11: TOXICOLOGICAL INFORMATION							
Dexmedesed <sup>™</sup> :	Acute toxicity	Irritation					
	Not Available	Not Available					
Dexmedetomidine hydrochloride:	Acute toxicity	Irritation					
	IV (mice/rats/dogs) highest non-lethal dose: 1mg/kg	Not available					
	IV (dog) LD <sub>50</sub> : 2mg/kg						
Sodium chloride:	Acute toxicity	Irritation					
	Oral (rat) LD <sub>50</sub> : 3000 mg/kg	Not available					
	Dermal (rabbit) LD <sub>50</sub> : >10,000 mg/kg						
	Inhalation (rat) LC <sub>50</sub> : >42 g/m³ (1-hr)						
	Oral (mouse) LD <sub>50</sub> : 4000 mg/kg						
Skin corrosion / irrita	tion:						
No information identifie	ed.						
Serious eye damage	/ irritation:						
No information identifie	ed.						
Respiratory or skin se	ensitization:						
No information identified.							
Germ cell mutagenicity:							
No information identified.							
Genotoxicity:							
Dexmedetomidine was negative for mutagenicity in the Ames assay, an <i>in vitro</i> forward							

Dexmedetomidine was negative for mutagenicity in the Ames assay, an *in vitro* forward mutation assay with mouse lymphoma cells, and was negative for chromosomal abberations (in human lymphocytes). However, it was positive for chromosomal aberrations with rat S9 metabolic activation, and was positive *in vivo* in the mouse micronucleus test with NMRI mice, but not with CD-1 mice. Overall, the mutagenicity data are difficult to interpret.

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 10 of 15



# Carcinogenicity:

No studies identified. None of the components of this mixture present at levels greater than or equal to 0.1% are listed by NTP, IARC, ACGIH or OSHA as a carcinogen.

# Reproductive Toxicity:

No effects on fertility were reported in rats given subcutaneous (SC) dexmedetomidine at doses up to 54 mg/kg/day. The NOAEL for systemic toxicity was 6 mg/kg/day.

# **Developmental Toxicity:**

Dexmedetomidine was administered SC to rats and IV to rabbits during gestation at doses up to 200 and 96 mg/kg/day, respectively. Increased post-implantation loss and a reduced number of live pups were noted in rats (NOAEL = 20 mg/kg/ day). No developmental/maternal toxicity was seen in rabbits (NOAEL = 96 mg/kg/ day).

In a multi-generational study, SC dexmedetomidine was administered to pregnant rats from gestational day 16 through nursing. Decreased pup weights were noted at doses  $\geq 8$  mg/kg/day. When pups born to mothers treated with 32 mg/kg/day were allowed to mature and mate, elevated embryo-fetal toxicity and delayed motor development was noted in their offspring. The NOAEL was 2 mg/kg/day.

## STOT – single exposure:

No information identified.

## STOT-repeated exposure:

Dexmedetomidine given IV to rats caused sedation, piloerection (hair standing up), and exophthalmos (abnormal eyeball protrusion) at 160 mg/kg/day. Small changes in thymus and body weights were reported at lower doses. A NOAEL of 40 mg/kg/ day was identified.

# Aspiration hazard:

No information identified.

## **SECTION 12: ECOLOGICAL INFORMATION**

# 12.1 Toxicity

Not Available

**DO NOT** discharge into sewer or waterways.

# 12.2 Persistence and degradability

Not Available

## 12.3 Bioaccumulative potential

Not Available

## 12.4 Mobility in Soil

Not Available

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 11 of 15



# 12.5 Results of PBT and vPvB assessment

Not Available

#### 12.6 Other adverse effects

Not data identified

## SECTION 13: DISPOSAL CONSIDERATIONS

## 13.1 Waste treatment methods

disposal:

Product / Dispose of wastes in accordance to prescribed federal, state, and local **packaging** guidelines, e.g., appropriately permitted chemical waste incinerator. Do not send down the drain or flush down the toilet. All wastes containing the material should be properly labeled. Rinse waters resulting from spill clean-ups should be discharged in an environmentally safe manner, e.g., appropriately permitted municipal or onsite wastewater treatment facility.

> Ensure that the disposal of material is carried out in accordance with Hazardous Substances (Disposal) Regulations (Canada 2015).

**Waste Treatment Options:** 

Not Available

Sewage Disposal Not Available

**Options:** 

# **SECTION 14: TRANSPORT INFORMATION**

Based on the available data, this mixture is not regulated as a hazardous material/ dangerous good under EU ADR/RID, US DOT, Canada TDG, IATA, or IMDG.

## Labels required:

Marine pollutant: NO

Hazchem: Not Applicable

# Land transport (ADR): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS

• '	<u>′</u>			
14.1 UN Number	N/a			
14.2 UN Proper Shipping Name	N/a			
14.3 Transport hazard class(es)	Class	N/a		
	Sub risk	N/a		
14.4 Packing group	N/a			
14.5 Environmental hazards	N/a			
14.6 Special precautions for user	Special provisions	N/a		
	Limited quantity	N/a		

Product Name: Dexmedesed<sup>TM</sup> (dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 12 of 15



14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a				
Air transport (ICAO-IDANGEROUS GOOD		ULATED FOR TRANSPORT OF			
14.1 UN Number	N/a				
14.2 UN Proper Shipping Name	N/a				
14.3 Transport	ICAO/IATA Class	N/a			
hazard class(es)	ICAO / IATA Sub risk	N/a			
	ERG Code	N/a			
14.4 Packing group	N/a				
14.5 Environmental hazards	N/a				
14.6 Special	Special provisions	N/a			
precautions for user	Cargo only packing instructions	N/a			
	Cargo only maximum qty/pack	N/a			
	Passenger and cargo packaging instructions	N/a			
	Passenger and cargo maximum qty/pack	N/a			
	Passenger and cargo limited quantity packing instructions	N/a			
	Passenger and cargo limited maximum qty/pack	N/a			
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a				
Sea transport (IMDG-Code / GGVSee): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS					
14.1 UN Number N/a					
	ı				

Product Name: Dexmedesed<sup>TM</sup> (dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 13 of 15



14.2 UN Proper Shipping Name	N/a					
14.3 Transport hazard class(es)	IMDG Class	N/a				
	IMDG Sub risk	N/a				
14.4 Packing group	N/a					
14.5 Environmental hazards	N/a					
14.6 Special	EMS Number	N/a				
precautions for user	Special provisions	N/a				
	Limited quantities	N/a				
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a					
Inland waterways transport (ADN): NOT REGULATED FOR TRANSPORT OF DANGEROUS GOODS						
14.1 UN Number	N/a					
14.2 UN Proper Shipping Name	N/a					
14.3 Transport hazard class(es)	N/a			N/a		
14.4 Packing group	N/a					
14.5 Environmental hazard	N/a					
14.6 Special precautions for user	Classification Code		N/a			
	Special provisions		N/a			
	Limited quantity		N/a			
	Equipment required		N/a			
	Fire cones number N/a					
14.7 Transport in bulk according to Annex II of MARPOL73/78 and the IBC Code	N/a					

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 14 of 15



# **SECTION 15: REGULATORY INFORMATION**

This SDS complies with the requirements under US, EU, Canada and GHS (EU CLP - Regulation EC No 1272/2008, WHMIS, 2015) guidelines. Consult your local/regional authorities for more information.

# Safety, health and environmental regulations/legislation specific for the substance or mixture

This SDS complies with the requirements under US, EU, Canada and GHS (EU CLP - Regulation EC No 1272/2008, WHMIS, 2015) guidelines. Consult your local/regional authorities for more information.

## Chemical safety assessment

Not conducted.

## **OSHA Hazardous**

No

## WHMIS classification

Not required. Drugs are not subject to WHMIS. This product has been classified in accordance with the hazard criteria of the Controlled Products Regulations and the SDS contains all of the information required by those regulations.

## TSCA status

Drugs are exempt from TSCA.

# **SARA** section 313

Not listed.

# California proposition 65

Not listed.

## **Additional information**

<u>Warning:</u> This packaging contains a chemical known to the State of California to cause cancer and birth defects or other reproductive harm.

# **SECTION 16: OTHER INFORMATION**

#### Revision date

07/12/2017

## Full text of R phrases and EU Classifications

Xn - Harmful. Repr. Cat. 3 - Toxic for Reproduction Category 3. R63 - Possible risk of harm to the unborn child.

# Full text of H phrases, P phrases and GHS classification

STOT-S3 - Specific Target Organ Toxicity Following Single Exposure Category 3. H336 - May cause drowsiness or dizziness. RT2 - Reproductive toxicity Category 2. H361d - Suspected of damaging the unborn child.

## Sources of data

Information from published literature and internal company data.

Product Name: Dexmedesed™

(dexmedetomidine hydrochloride) Sterile

Injectable Solution Issue Date: 07/12/2017

Version No: 1 Page 15 of 15



#### **Abbreviations**

ACGIH - American Conference of Governmental Industrial Hygienists; ADR/RID - European Agreement Concerning the International Carriage of Dangerous Goods by Road/Rail; AIHA -American Industrial Hygiene Association; CAS# - Chemical Abstract Services Number; CLP -Classification, Labelling, and Packaging of Substances and Mixtures; DNEL - Derived No. Effect Level; DOT - Department of Transportation; EINECS - European Inventory of New and Existing Chemical Substances; ELINCS - European List of Notified Chemical Substances; EU - European Union; GHS - Globally Harmonized System of Classification and Labeling of Chemicals; IARC - International Agency for Research on Cancer; IDLH - Immediately Dangerous to Life or Health; IATA - International Air Transport Association; IMDG -International Maritime Dangerous Goods; LOEL - Lowest Observed Effect Level; LOAEL -Lowest Observed Adverse Effect Level; NIOSH - The National Institute for Occupational Safety and Health; NOEL - No Observed Effect Level; NOAEL - No Observed Adverse Effect Level; NTP - National Toxicology Program; OEL - Occupational Exposure Limit; OSHA -Occupational Safety and Health Administration; PNEC - Predicted No Effect Concentration; SARA - Superfund Amendments and Reauthorization Act; STEL - Short Term Exposure Limit; TDG - Transportation of Dangerous Goods; TSCA - Toxic Substances Control Act; TWA -Time Weighted Average: WHMIS - Workplace Hazardous Materials Information System

## Disclaimer

The above information is based on data available to us and is believed to be correct. Since the information may be applied under conditions beyond our control and with which we may be unfamiliar, we do not assume any responsibility for the results of its use and all persons receiving it must make their own determination of the effects, properties and protections which pertain to their particular conditions.

No representation, warranty, or guarantee, express or implied (including a warranty of fitness or merchantability for a particular purpose), is made with respect to the materials, the accuracy of this information, the results to be obtained from the use thereof, or the hazards connected with the use of the material. Caution should be used in the handling and use of the material because it is a pharmaceutical product.

The above information is offered in good faith and with the belief that it is accurate. As of the date of issuance, we are providing all information relevant to the foreseeable handling of the material. However, in the event of an adverse incident associated with this product, this Safety Data Sheet is not, and is not intended to be, a substitute for consultation with appropriately trained personnel.